Issue: January/February 2017, Posted Date: 2/17/2017

Ascendia Pharmaceuticals Announces Issuance of New Patent for Acute Coronary Syndrome Program

Ascendia Pharmaceuticals, a specialty pharmaceutical company engaged in nano-formulation  design, development, and manufacture for poorly soluble molecules, recently announced it has been awarded a new patent. US Patent No. 9,480,680, titled Stable Pharmaceutical Composition of Clopidogrel Free Base for Oral and Parenteral Delivery, describes the application of Ascendia's EmulSol nanotechnology to formulate a stable, ready-to-use, rapid-onset, injectable form of clopidogrel.


About ASD-002

Clopidogrel, a top-selling blood thinner medicine, has never been successfully developed in an injectable dosage form due to its inherent chemical instability and poor solubility.


“There is a significant unmet medical need for a parenteral clopidogrel dosage form for the treatment of Acute Coronary Syndrome under life-threatening situations,” said Jingjun “Jim” Huang, PhD, CEO of Ascendia. “With our nanoemulsion platform technology, Ascendia has demonstrated that a ready-to-use, stable, and soluble, parenteral form of clopidogrel is both technically and commercially feasible.”  


When a patient presents with a suspected coronary event, a high oral dose of clopidogrel is frequently administered as the only available forms of clopidogrel are tablets - not ideal in an emergency setting.  Also, when delivered orally, there is a significant delay in the time required for the medicine to become fully absorbed and effective.


ASD-002 can be administered as a single high-dose injection of clopidogrel, capable of overcoming CYP2C19 resistance in a percutaneous coronary intervention (PCI) setting (which 30% of patients experience). Thus ASD-002 will address the unmet need for rapid platelet inhibition, while reducing bleeding risk, associated with newer P2Y12 agents, and has the potential to expand the $2 billion PCI market in peripheral artery disease. ASD-002 for injection also has the potential to provide an advantage compared to the recently approved IV anti-thrombotic drug cangrelor, as ASD-002 should not have an indication exclusion for patients currently on a P2Y12 inhibitor.


About Ascendia Pharmaceuticals LLC
Ascendia is a specialty pharmaceutical company dedicated to developing enhanced formulations of existing drug products, and enabling formulations for preclinical and clinical stage drug candidates. We specialize in creating formulation solutions for poorly water-soluble molecules and other challenging pharmaceutical development projects. Ascendia formulates products for injection (IV, SC or IM); transdermal, ophthalmic, or nasal delivery; and both immediate-release and controlled-release products for oral administration. We have three technology platforms - EmulSol for producing nano-emulsions, AmorSol for creating amorphous solid dispersions, and NanoSol for formulating nano-particles. For more information, visit Ascendia at



Jinjung "Jim" Huang, PhD, CEO
Ascendia Pharmaceuticals

This record has been viewed 793 times.


Click here to see the showcases

BIO Investor Forum
October 17-18, 2017
The Westin St. Francis, San Francisco, CA US
Partnership Opportunities in Drug Delivery (PODD)
October 19-20
Boston, MA

CPhI Worldwide
October 24-26
Frankfurt, Germany

Universe of Prefilled Syringes & Injection Devices Europe
November 7-8
Vienna, Austria

November 12-17
San Diego, CA

Pre-Filled Syringes Europe
January 17-18, 2018
Copthorne Tara Hotel, London UK

Drug Delivery Partnerships
January 22-24 Palm Beach, FL

3rd Annual Drug Development Networking Summit
March 8, 2018  Hilton Hotel Parsippany NJ
PDA Annual Meeting
March 19-21 Orlando, FL
CPhI North America
April 24-26 Philadelphia, PA 
April 17-19 New York City
RDD (Respiratory Drug Delivery)
April 22-26 Tucson, AZ
BIO 2018
June 4-7 Boston, MA
Controlled Release Society Meeting
July 23-25 New York City
Universe of Prefilled Syringes & Injection Devices
October 8-9 Orlando, FL

Copyright © 2017  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions